In the second study, a Phase I clinical trial, baseline glutamine PET imaging with 11C-Glutamine and 18F-FSPG is evaluated in patients with metastatic WT KRAS CRC undergoing treatment with EGFR-targeted antibody therapy (ClinicalTrials.gov ID: NCT03275974). Here, KRAS is linked to colorectal carcinoma.